April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Worldwide Experiences With Intravitreal Anti-VEGFs for ROP
Author Affiliations & Notes
  • Edgard Omar Rodriguez Torres, Sr.
    Ophthalmology,
    Asociacion para Evitar la Ceguera en Mexico (APEC), Mexico, Mexico
  • Maria A. Martinez
    Retina,
    Asociacion para Evitar la Ceguera en Mexico (APEC), Mexico, Mexico
  • Hugo Quiroz Mercado
    Retina,
    Asociacion para Evitar la Ceguera en Mexico (APEC), Mexico, Mexico
  • Jose L. Guerrero Naranjo
    Retina,
    Asociacion para Evitar la Ceguera en Mexico (APEC), Mexico, Mexico
  • Wu Wei Chi
    Ophthalmology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
  • Robison V. Paul Chan
    Ophthalmology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York
  • Kuo His Kung
    Ophthalmology, Chang Gung Memorial Hospital - Kaohsiung Medical Center, Kaohsiung, Taiwan
  • Alay S. Banker
    Ophthalmology, Banker′s Retina Clinic and Laser Center, Ahmedabad, India
  • Footnotes
    Commercial Relationships  Edgard Omar Rodriguez Torres, Sr., None; Maria A. Martinez, None; Hugo Quiroz Mercado, None; Jose L. Guerrero Naranjo, None; Wu Wei Chi, None; Robison V. Paul Chan, St. Giles Foundation and from a departmental grant from research to prevent blindness (F); Kuo His Kung, None; Alay S. Banker, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3125. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Edgard Omar Rodriguez Torres, Sr., Maria A. Martinez, Hugo Quiroz Mercado, Jose L. Guerrero Naranjo, Wu Wei Chi, Robison V. Paul Chan, Kuo His Kung, Alay S. Banker; Worldwide Experiences With Intravitreal Anti-VEGFs for ROP. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3125.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the efficacy of intravitreal anti-VEGF agents in ROP.

Methods: : Multicentered study of 247 eyes with ROP (stage 3 and 4) treated with intravitreal anti-VEGFs (221, bevacizumab; 16, pegaptanib; 10, ranibizumab), with laser (59 eyes) and without laser (188 eyes). Birth weight and gestational age ranged from 700 to 962 grams and 24-29 weeks, respectively.

Results: : All eyes showed regression of neovascularization and normal vascular growth. Only 4 eyes had transient vitreous hemorrhage, and 10 eyes needed vitrectomy. No systemic adverse events were observed in up to 4 years follow-up.

Conclusions: : Intravitreal anti-VEGF drugs may be safe and effective in the treatment of ROP.

Clinical Trial: : http://www.clinicaltrials.gov NCT00346814

Keywords: retinopathy of prematurity • vascular endothelial growth factor • retinal neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×